Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory

Affiliations

• ¹ Division of Research, Kaiser Permanente Northern California, San Francisco, California, USA; Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA. Electronic address: Ankeet.s.bhatt@kp.org.
• ² Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
• ³ Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
• ⁴ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• ⁵ Division of Cardiology, Mount Sinai University Hospital, New York, New York, USA.
• ⁶ S & S Consulting Partners LLC, Silver Spring, Maryland, USA.
• ⁷ Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
• ⁸ Inova Schar Heart and Vascular, Falls Church, Virginia, USA.
• ⁹ Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
• ¹⁰ Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health System, Dallas, Texas, USA.
• ¹¹ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
• ¹² Division of Cardiology, Department of Medicine, University of California-San Diego, San Diego, California, USA.
• ¹³ Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Inova Schar Heart and Vascular, Falls Church, Virginia, USA.